Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anamorelin HCl in Advanced NSCLC With Cachexia
NCT03743051Phase 3Completed
- Sponsor
- Helsinn
- Start
- Mar 2019
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in cachexia comparing 100 mg anamorelin HCl with placebo (2 arms). Primary endpoints: Mean Change From Baseline in Body Weight at 12 weeks and Mean Change From Baseline in 5-item Anorexia Symptom Subscale at 12 weeks. Started Mar 2019; status: completed.
02
Drugs
anamorelin
03
Conditions
cachexia
Beyond the preview
Go deeper on NCT03743051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03743051.